Ignite Creation Date:
2024-05-05 @ 11:56 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00189280
Status:
COMPLETED
Last Update Posted:
2022-02-22
First Post:
2005-09-12
Brief Title:
Aldara for the Treatment of Large andor Multiple sBCC
Sponsor:
MEDA Pharma GmbH Co KG
Organization:
Viatris Inc
Study Overview
Official Title:
Open Study to Evaluate the Efficacy and Tolerance of Imiquimod 5 Cream for the Treatment of a Large andor Multiple Superficial Basal Cell Carcinoma
Status:
COMPLETED
Status Verified Date:
2008-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
BCC is the most common form of skin cancer Current treatment is often surgery but this can be limited by the number of lesions their location the age of the patient or the potential cosmetic outcome The purpose of this study is to evaluate the effectiveness of imiquimod on a non surgical treatment in subjects with multiple of large sBCCs
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None